It is estimated that alcohol contributes to around three million deaths worldwide per year. That is about five percent of all deaths each year. The major causes of alcohol-related death include alcohol poisoning, liver damage, heart failure, cancer, and car accidents.

Alcohol abuse worldwide Despite the widespread use of alcohol around the world, a global survey from 2021 of people from 30 different countries, found that around 11 percent of respondents stated alcohol abuse was the biggest health problem facing people in their country. It is currently estimated that around 1.38 percent of the global population has alcohol use disorder, however binge drinking and excessive alcohol use, both of which carry health risks, are much more common. The countries with the highest per capita consumption of alcohol include Czechia, Latvia, and the Republic of Moldova.

Alcohol consumption in the United States It is estimated that around 60 percent of adults in the United States aged 21 to 49 years currently use alcohol. Binge drinking (four or more drinks for women and five or more drinks for men on a single occasion) is most common among those aged 21 to 25 years, but still around 29 percent of those aged 40 to 44 report binge drinking. The states with the highest share of the population who binge drink are Wisconsin, North Dakota, and Montana. The death rate due to alcohol in the United States was around 13 per 100,000 population in 2020, an increase from a rate of 10.4 per 100,000 recorded in 2019.

This statistic depicts the distribution of alcohol-related deaths globally by broad disease category as of 2016. According to the data, 21.3 percent of deaths due to alcohol were related to digestive diseases.

In 2021, about 1,350 alcohol-related deaths were registered in Italy. This statistic breaks this figure down by specific diseases that caused the deaths of individuals. According to the data, during that year, 948 people died due to alcohol-induced liver diseases. Furthermore, there were 326 deaths attributable to alcohol-induced psychosis. This graph shows the number of alcohol-related deaths in Italy in 2021, by disease.

As of 2022, men accounted for around 75 percent of alcohol-related deaths in Finland. That year, 1,251 men and 413 women died of alcohol poisoning or alcohol-related disease in Finland. While the number of alcohol-related deaths declined from 2012 to 2022, men consistently had a higher death rate throughout this period.

BackgroundCardiovascular diseases (CVDs) are the leading global disease burden, with alcohol consumption closely linked to their occurrence. This study analyzes data from the Global Burden of Disease Study 2021 (GBD 2021) to assess the distribution and trends of high alcohol use-related CVD from 1990 to 2021 across global, regional, and national levels.Materials and methodsWe used the data from the GBD 2021 to conduct stratification by region, country, gender, age, SDI, and disease type in terms of the number of deaths, age-standardized mortality rate (ASMR), disability-adjusted life years (DALYs), age-standardized rate of DALYs (ASDR), years lived with disability (YLDs), age-standardized rate of YLDs, years of life lost (YLLs), and age-standardized rate of YLLs to comprehensively assess the burden of high alcohol use-related CVD from 1990 to 2021. All statistical analyses in this study were performed using R statistical software (version 4.1.2).ResultsBetween 1990 and 2021, global deaths, DALYs, YLDs, and YLLs attributable to high alcohol use-related CVD showed notable variation. By 2021, global deaths had doubled compared to 1990, while ASMR, ASDR, age-standardized YLD rate, and YLL rate all declined. Eastern Europe had the highest rates in 2021. Males consistently had higher ASMR, ASDR, YLD, and YLL rates compared to females, with the highest number of deaths occurring in the 70–74 age group, and the 65–69 age group showing the highest DALYs, YLDs, and YLLs. These rates increased with age. Stroke was the most common high alcohol use-related CVD, while ischemic heart disease (IHD) was the least common.ConclusionBetween 1990 and 2021, the overall burden of high alcohol use-related CVD declined globally, though some regions experienced an increase. This highlights the need for continued public health efforts, particularly targeting high-risk regions and populations, to mitigate the impact of alcohol on cardiovascular health.

Data underlying figures and relative risk curves within the article. Provides readers the mean value and uncertainty intervals for prevalence of current drinking, drinks per day by location, relative risks by outcome and dose, along with results for the weighted all-cause relative risk curve used to justify TMREL within the study. Based off sources mentioned in Appendix I.

From Abstract in linked paper:

Background Alcohol use is a leading risk factor for death and disability, but its overall association with health remains complex given the possible protective effects of moderate alcohol consumption on some conditions. With our comprehensive approach to health accounting within the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we generated improved estimates of alcohol use and alcohol-attributable deaths and disability-adjusted life-years (DALYs) for 195 locations from 1990 to 2016, for both sexes and for 5-year age groups between the ages of 15 years and 95 years and older.

Methods Using 694 data sources of individual and population-level alcohol consumption, along with 592 prospective and retrospective studies on the risk of alcohol use, we produced estimates of the prevalence of current drinking, abstention, the distribution of alcohol consumption among current drinkers in standard drinks daily (defined as 10 g of pure ethyl alcohol), and alcohol-attributable deaths and DALYs. We made several methodological improvements compared with previous estimates: first, we adjusted alcohol sales estimates to take into account tourist and unrecorded consumption; second, we did a new meta-analysis of relative risks for 23 health outcomes associated with alcohol use; and third, we developed a new method to quantify the level of alcohol consumption that minimises the overall risk to individual health

This statistic shows the top ten countries with the highest alcohol-related mortality rates in 2012. Belarus, Ukraine, Moldova, Lithuania, and Russia made it to the top 5. Belarus was leading the ranking with roughly 35 percent of alcohol-attributable deaths in 2012.

This statistic depicts the percentage of alcohol-related deaths globally as a percentage of deaths from select diseases in 2016. According to the data, among deaths due to liver cirrhosis, 48 percent were related to alcohol use.

BackgroundColorectal cancer (CRC) ranks among the highest in incidence and mortality rates globally. A significant portion of Colorectal cancer cases and deaths can be attributed to modifiable risk factors, with smoking, alcohol use, and high body mass index (BMI) being the three most prominent. However, the impact of these risk factors on Colorectal cancer across regions, genders, and age groups remains insufficiently characterized.MethodsUtilizing data from the Global Burden of Disease (GBD) study 2019, restrictive cubic splines (RCS) and quantile regression analyses are applied to explore the relationship between the Socio-Demographic Index (SDI) and ASMR or ASDR. Additionally, gender differences, changes across different SDI levels, and age group trends in smoking, alcohol use, and high BMI over the 30-year period are analyzed. The Bayesian age-period-cohort (BAPC) model is employed to predict mortality trends from 2020 to 2030, aiming to explore the epidemiological and sociodemographic transitions in the Colorectal cancer disease burden attributed to smoking, alcohol use, and high BMI.ResultsIn 2019, the number of colorectal cancer deaths globally attributable to risk factors as smoking, alcohol consumption, and obesity increased to 142,931, 52,495, and 85,882 cases respectively, collectively accounting for approximately one-third of all Colorectal cancer-related deaths. Notably, there is an upward trend in early-onset Colorectal cancer mortality associated with these factors.DiscussionTo reduce the burden of Colorectal cancer, it is recommended to enhance health education, promote smoking cessation and alcohol moderation, and increase the coverage and participation in Colorectal cancer screening, which are crucial for lowering Colorectal cancer mortality rates. These findings are vital for the development of public health policies and intervention measures to reduce the global disease burden. They provide guidance for Colorectal cancer prevention across different regions, genders, and age groups worldwide.

According to Cognitive Market Research, the Global Alcoholic Hepatiti Drug Market Size is USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2024 to 2033.

North America held largest share of XX% in the year 2024 
Europe held share of XX% in the year 2024 
Asia-Pacific held significant share of XX% in the year 2024 
South America held significant share of XX% in the year 2024
Middle East and Africa held significant share of XX% in the year 2024 

Market Dynamics of the Alcoholic Hepatiti Drug

Key Driver for the Alcoholic Hepatiti Drug Market

Rising Prevalence of Alcoholic Liver Diseases is driving the growth of market

Increased alcohol consumption worldwide is a primary driver, leading to more cases of liver damage and inflammation, including alcoholic hepatitis Alcoholic liver diseases (ALD), including alcoholic hepatitis and cirrhosis, have emerged as a serious public health issue across the globe, mainly prompted by rising alcohol intake. Alcohol use accounted for about 2.6 million fatalities worldwide , with 4.7% of all deaths worldwide. It was particularly significant that 13% of those deaths were among those aged between 20 and 39 years. The worldwide burden of alcohol related compensated cirrhosis was estimated at 23.6 million cases, while decompensated cirrhosis was present in another 2.5 million patients. This huge morbidity is most dominant in Western and Central Europe, where liver diseases due to alcohol are the most dominant. New evidence shows an alarming increase in ALD among young populations. Queens University, Ontario, found a sharp rise in alcohol related liver and pancreas complications among people under the age of 40, with 13.5% of global deaths in this age bracket caused by alcohol. In India, the prevalence of alcohol related cirrhosis and other chronic liver conditions was significantly high, with age standardized rates showing an increasing trend from 1990 to 2019. This highlights the critical need for successful public health measures and policies to combat the increasing burden of ALD, especially among young adults. These figures underscore the urgent necessity of holistic public health measures to combat the effects of alcohol drinking on liver health in the world.

Key Restraints for the Alcoholic Hepatiti Drug Market

Encouraging patients to abstain from alcohol and adhere to treatment plans can be difficult which can hamper the growth of market

Forcing compliance among Alcohol Use Disorder (AUD) patients means overcoming a range of physical, psychological, and social obstacles. An Indian study revealed that 99% of the sample mentioned conflicts with time as the primary concern, as patients find it difficult to reconcile going to treatment with everyday obligations. Options like telemedicine or non-traditional treatment schedules could enhance attendance and participation. Moreover, 68% of the participants identified fear of treatment, based on concerns about withdrawal, stigmatization, or the perceived severity of treatments. Patient education and clear communication can address these fears. Denial or ignorance regarding the harmful effects of alcohol consumption, as indicated by 80.5% of the respondents, is also a major challenge. Public health interventions, motivational interviewing, and family involvement during treatment can assist in helping individuals acknowledge the need for intervention. Social stigma and absence of support systems, indicated by 49%, also compound treatment adherence, and it is hence important to develop supportive, non-judgmental settings that promote recovery. Nonadherence to medications is also a problem, with disparate adherence rates for drugs such as naltrexone and disulfiram. Tailored interventions and enhanced communication between patients and healthcare professionals can alleviate medication concerns. A comprehensive treatment strategy—employing therapies such as cognitive-behavioural therapy (CBT) and motivational enhancement therapy (MET)—is essential for improving long-term recovery. By addressing these obstacles in an extensive manner, we can enhance patient participation and optimize treatment effects for AUD.

Introduction of Alcoholic Hepatiti Drug Market

The international market for alcoholic hepatitis (AH) medici...

BackgroundLiver cirrhosis-related death is a serious threat worldwide. The number of studies exploring the mortality trend of cirrhosis caused by specific etiologies was limited. This study aimed to demonstrate the pattern and trend based on the data of global burden of disease (GBD).MethodsThe data of cirrhosis mortality were collected from the GBD 2017. The Age standardized mortality rate (ASR) and estimated annual percentage changes (EAPC) were used to estimate the temporal trend of liver cirrhosis mortality by etiologies, regions, sociodemographic index (SDI), and sexes.ResultsGlobally, mortality cases of cirrhosis increased by 47.15%. Although the global ASR of cirrhosis mortality remained stable during this period, the temporal trend varied in etiologies. The ASR of mortality caused by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis (NASH) increased with an EAPC of 0.17 (95% CI, 0.14–0.20), 0.20 (95% CI, 0.16–0.24), 1.00 (95% CI, 0.97–1.04), respectively. A decreasing trend of ASR was found among the causes of hepatitis B virus (BV) and other causes. The increased pattern was heterogeneous worldwide. The most pronounced increase trend was found in middle-high SDI regions and Eastern Europe. Contrarily, the most pronounced decrease trend was found in low SDI regions and Western Sub-Saharan Africa.ConclusionCirrhosis is still a public health problem. The growth trend of cirrhosis mortality caused by HCV was slowed by promoting direct-acting antiviral therapy. Unfortunately, we observed an unfavorable trend in etiologies for alcohol consumption and NASH, which indicated that more targeted and specific strategies should be established to limit alcohol consumption and promote healthy lifestyles in high-risk countries, especially in middle-high SDI regions and Eastern Europe.

ObjectiveTo examine the incidence of cardiomyopathy including both alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC) in 204 nations and regions over the 1990–2019 period.MethodsThe present study was conducted using data derived from the GBD 2019 study coordinated by the Institute for Health Metrics and Evaluation (IHME). The GBD 2019 study included epidemiological data pertaining to 369 diseases/injuries, 286 causes of death, and 87 risk factors in 204 nations and regions. For this study, we adopt published estimates pertaining to the prevalence rates, mortality rates, and disability-adjusted life years (DALYs) associated with cardiomyopathy. The Bayesian mixed-effects DisMod-MR 2.1 meta-regression tool, which was designed to analyze GBD data, was used to estimate the prevalence of OC and AC. The GBD data are subdivided into 21 global regions based on characteristics such as geographical proximity and epidemiological similarity. The overall burden of cardiomyopathy was assessed by combining AC- and OC-related data, 95% confidence intervals were calculated based on standardized error values determined based upon the width of the 95% UI divided by 1.96 × 2.ResultsGlobally, there were an estimated 0.71 million (95% UI: 0.55–0.92) AC cases and 3.73 million (95% UI: 2.92–4.72) OC cases in 2019. The age-standardized cardiomyopathy, AC, and OC prevalence rates (per 100,000 persons) in 2019 were 56.0 (95% CI: 43.82–71.17), 8.51 (95% UI: 6.6–11.01), and 47.49 (95% UI: 37.22–60.16), respectively. In total, the respective numbers of global deaths attributed to AC and OC were 0.07 million (95% UI: 0.06–0.08) and 0.24 million (95% UI: 0.19–0.26). The age-standardized mortality rate for cardiomyopathy in 2019 was 3.97 (95% CI: 3.29–4.39), with respective mortality rates of 0.86 (95% UI: 0.72–0.99) and 3.11 (95% UI: 2.57–3.4) for AC and OC. At the global level in 2019, 2.44 million (95% UI: 2.04–2.78) DALYs were attributed to AC, while 5.72 million (95% UI: 4.89–6.33) DALYs were attributed to OC. From 1990 to 2019, cardiomyopathy age-standardized prevalence rates declined by −0.49% (95% CI: −0.57 to −0.41), with those for AC and OC having respectively declined by −0.32% (95% UI: −0.36 to −0.28) and −0.17% (95% UI: −0.21 to −0.13). The age-standardized AC and OC mortality rates declined by −0.36% (95% UI: −0.5 to −0.26) and −0.39% (95% UI: −0.44 to −0.29), despite 24.8 and 30.2% increases, respectively, in the numbers of AC- and OC-related deaths during the same period.ConclusionPrevious studies have estimated the risk factors that influence the burden of multiple cardiovascular diseases (CVD). Among them, some studies related to the GBD database on cardiomyopathy data suggest that alcohol intake, gender are factors in the development of AC, and the burden of AC and OC is not limited to developed or less developed countries. Otherwise, this study mainly focused on cardiomyopathy, and analyzed multiple indicators from national, regional, and age-standard dimensions to identify potential risk factors including prevalence, deaths, years lived with Disability-adjusted life years (DALYs) that influence the development of AC and OC. To our knowledge, this study is the first to have systematically assessed the burden of AC and OC as of 2019 at the national, regional, and global levels and calculated DALYs to achieve a better evaluation of disease risk and quality of life of the population. The number of cases, deaths and DALYs of cardiomyopathy showed an overall increasing trend and obvious geographical differences in the past three decades. The burden of cardiomyopathy remains a persistent threat to global public health. These results provide an epidemiological foundation that can guide public health efforts and policymakers.

Abstract Out of the deaths that occurred in 2012 worldwide, 5.9% were caused by harmful consumption of alcohol (WHO, 2014). In Argentina, during 2008 there were 11,013 deaths attributed to alcohol consumption (3.6% of total deaths in population) (ACOSTA, BERTONE e PELÁEZ, 2012). Alcohol consumption per capita by people aged 15 and over in Argentina remained at around 9.5 liters of pure alcohol (equivalent to 25 grams of alcohol per day), considering average figures for the years 2003-2005 and 2008-2010 (WHO, 2014). This quantitative, descriptive and cross-sectional study aims to analyze mortality attributable to alcohol consumption in the provinces of the Argentinian Northwest in 2011, and how this affects life expectancy of these populations. The methodologies proposed by the CDC (1990) - Mortality Attributable to Alcohol Consumption (MACA) and Years of Lost Life Expectancy (AEVP) have been applied (ARRIAGA, 1996). Data provided by DEIS (vital statistics) and INDEC (EnPreCoSP-2011 and population projections) have been used. This article seeks to provide updated information on the status of mortality attributable to alcohol consumption, which is a contribution to public health in order to assess the implementation of appropriate strategies.

Online Alcohol Therapy Service Market Outlook

In 2023, the global market size for online alcohol therapy services was valued at approximately $2.5 billion, and it is projected to reach $6.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 11.7%. This substantial growth is driven by several factors, including increased awareness about mental health, the convenience of online therapy, and rising alcohol addiction rates worldwide.

One of the primary growth factors for the online alcohol therapy service market is the increasing awareness and destigmatization of mental health issues. Over the past decade, various campaigns and initiatives have contributed to the public's understanding of mental health, making it more acceptable to seek help. This has particularly impacted the therapy services sector, as more individuals are now comfortable reaching out for help, especially through more private and convenient online platforms. Additionally, the COVID-19 pandemic highlighted the importance of mental health and the need for accessible treatment options, further propelling the market's growth.

Another significant growth factor is the convenience and accessibility of online therapy services. Unlike traditional in-person therapy, online services offer flexibility by allowing individuals to schedule sessions that fit their schedules and attend them from the comfort of their homes. This eliminates many barriers associated with traditional therapy, such as transportation issues, geographical limitations, and the stigma of attending therapy sessions physically. As a result, more people are opting for online therapy, contributing to the market's growth.

The rising incidence of alcohol addiction and related disorders is also a crucial driver for the market. According to the World Health Organization (WHO), alcohol consumption contributes to over 3 million deaths globally each year. This has increased the demand for effective treatment options, including online therapy services. The anonymity and privacy offered by online platforms make them an attractive option for individuals seeking help without the fear of judgment. Moreover, advancements in technology have enabled the development of more interactive and engaging therapy platforms, enhancing the overall user experience and treatment outcomes.

From a regional perspective, North America currently holds the largest share of the online alcohol therapy service market, driven by high internet penetration, advanced healthcare infrastructure, and a robust mental health awareness culture. Europe follows closely, with significant contributions from countries like the UK, Germany, and France. The Asia Pacific region is expected to witness the fastest growth, fueled by rising alcohol consumption rates, increasing awareness about mental health, and the proliferation of digital platforms. Latin America and the Middle East & Africa are also showing promising growth potential, although at a slower pace compared to other regions.

Service Type Analysis

The online alcohol therapy service market is segmented by service type into individual counseling, group therapy, family therapy, and others. Individual counseling is currently the most prominent segment, as it offers personalized treatment plans tailored to the specific needs of the individual. This type of service allows for one-on-one interactions with therapists, enabling a more focused and private approach to addressing alcohol addiction. The flexibility and confidentiality of individual counseling make it a preferred choice for many seeking help online.

Group therapy is another significant segment within the market, known for its efficacy in creating a supportive environment among peers facing similar challenges. Online group therapy sessions allow individuals to share their experiences, offer mutual support, and learn from others' coping strategies. This segment is particularly beneficial for those who thrive in a communal setting and seek to build a network of support during their recovery journey. The ability to connect with others facing similar issues can be a powerful motivator for individuals struggling with alcohol addiction.

Family therapy is also gaining traction, as it involves the participation of family members in the treatment process. This type of therapy aims to address the dynamics within the family that may contribute to or be affected by an individual's alcohol addiction. Online family therapy sessions provide a convenient way for families to engage in the treatment process, regardles

Goal 3Ensure healthy lives and promote well-being for all at all agesTarget 3.1: By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live birthsIndicator 3.1.1: Maternal mortality ratioSH_STA_MORT: Maternal mortality ratioIndicator 3.1.2: Proportion of births attended by skilled health personnelSH_STA_BRTC: Proportion of births attended by skilled health personnel (%)Target 3.2: By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live birthsIndicator 3.2.1: Under-5 mortality rateSH_DYN_IMRTN: Infant deaths (number)SH_DYN_MORT: Under-five mortality rate, by sex (deaths per 1,000 live births)SH_DYN_IMRT: Infant mortality rate (deaths per 1,000 live births)SH_DYN_MORTN: Under-five deaths (number)Indicator 3.2.2: Neonatal mortality rateSH_DYN_NMRTN: Neonatal deaths (number)SH_DYN_NMRT: Neonatal mortality rate (deaths per 1,000 live births)Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseasesIndicator 3.3.1: Number of new HIV infections per 1,000 uninfected population, by sex, age and key populationsSH_HIV_INCD: Number of new HIV infections per 1,000 uninfected population, by sex and age (per 1,000 uninfected population)Indicator 3.3.2: Tuberculosis incidence per 100,000 populationSH_TBS_INCD: Tuberculosis incidence (per 100,000 population)Indicator 3.3.3: Malaria incidence per 1,000 populationSH_STA_MALR: Malaria incidence per 1,000 population at risk (per 1,000 population)Indicator 3.3.4: Hepatitis B incidence per 100,000 populationSH_HAP_HBSAG: Prevalence of hepatitis B surface antigen (HBsAg) (%)Indicator 3.3.5: Number of people requiring interventions against neglected tropical diseasesSH_TRP_INTVN: Number of people requiring interventions against neglected tropical diseases (number)Target 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-beingIndicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory diseaseSH_DTH_NCOM: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease (probability)SH_DTH_NCD: Number of deaths attributed to non-communicable diseases, by type of disease and sex (number)Indicator 3.4.2: Suicide mortality rateSH_STA_SCIDE: Suicide mortality rate, by sex (deaths per 100,000 population)SH_STA_SCIDEN: Number of deaths attributed to suicide, by sex (number)Target 3.5: Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcoholIndicator 3.5.1: Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disordersSH_SUD_ALCOL: Alcohol use disorders, 12-month prevalence (%)SH_SUD_TREAT: Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders (%)Indicator 3.5.2: Alcohol per capita consumption (aged 15 years and older) within a calendar year in litres of pure alcoholSH_ALC_CONSPT: Alcohol consumption per capita (aged 15 years and older) within a calendar year (litres of pure alcohol)Target 3.6: By 2020, halve the number of global deaths and injuries from road traffic accidentsIndicator 3.6.1: Death rate due to road traffic injuriesSH_STA_TRAF: Death rate due to road traffic injuries, by sex (per 100,000 population)Target 3.7: By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmesIndicator 3.7.1: Proportion of women of reproductive age (aged 15–49 years) who have their need for family planning satisfied with modern methodsSH_FPL_MTMM: Proportion of women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (% of women aged 15-49 years)Indicator 3.7.2: Adolescent birth rate (aged 10–14 years; aged 15–19 years) per 1,000 women in that age groupSP_DYN_ADKL: Adolescent birth rate (per 1,000 women aged 15-19 years)Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for allIndicator 3.8.1: Coverage of essential health servicesSH_ACS_UNHC: Universal health coverage (UHC) service coverage indexIndicator 3.8.2: Proportion of population with large household expenditures on health as a share of total household expenditure or incomeSH_XPD_EARN25: Proportion of population with large household expenditures on health (greater than 25%) as a share of total household expenditure or income (%)SH_XPD_EARN10: Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%)Target 3.9: By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contaminationIndicator 3.9.1: Mortality rate attributed to household and ambient air pollutionSH_HAP_ASMORT: Age-standardized mortality rate attributed to household air pollution (deaths per 100,000 population)SH_STA_AIRP: Crude death rate attributed to household and ambient air pollution (deaths per 100,000 population)SH_STA_ASAIRP: Age-standardized mortality rate attributed to household and ambient air pollution (deaths per 100,000 population)SH_AAP_MORT: Crude death rate attributed to ambient air pollution (deaths per 100,000 population)SH_AAP_ASMORT: Age-standardized mortality rate attributed to ambient air pollution (deaths per 100,000 population)SH_HAP_MORT: Crude death rate attributed to household air pollution (deaths per 100,000 population)Indicator 3.9.2: Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (exposure to unsafe Water, Sanitation and Hygiene for All (WASH) services)SH_STA_WASH: Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)Indicator 3.9.3: Mortality rate attributed to unintentional poisoningSH_STA_POISN: Mortality rate attributed to unintentional poisonings, by sex (deaths per 100,000 population)Target 3.a: Strengthen the implementation of the World Health Organization Framework Convention on Tobacco Control in all countries, as appropriateIndicator 3.a.1: Age-standardized prevalence of current tobacco use among persons aged 15 years and olderSH_PRV_SMOK: Age-standardized prevalence of current tobacco use among persons aged 15 years and older, by sex (%)Target 3.b: Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for allIndicator 3.b.1: Proportion of the target population covered by all vaccines included in their national programmeSH_ACS_DTP3: Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)SH_ACS_MCV2: Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)SH_ACS_PCV3: Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)SH_ACS_HPV: Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) (%)Indicator 3.b.2: Total net official development assistance to medical research and basic health sectorsDC_TOF_HLTHNT: Total official development assistance to medical research and basic heath sectors, net disbursement, by recipient countries (millions of constant 2018 United States dollars)DC_TOF_HLTHL: Total official development assistance to medical research and basic heath sectors, gross disbursement, by recipient countries (millions of constant 2018 United States dollars)Indicator 3.b.3: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basisSH_HLF_EMED: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis (%)Target 3.c: Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing StatesIndicator 3.c.1: Health worker density and distributionSH_MED_DEN: Health worker density, by type of occupation (per 10,000 population)SH_MED_HWRKDIS: Health worker distribution, by sex and type of occupation (%)Target 3.d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risksIndicator 3.d.1: International Health Regulations (IHR) capacity and health emergency preparednessSH_IHR_CAPS: International Health Regulations (IHR) capacity, by type of IHR capacity (%)Indicator 3.d.2: Percentage of bloodstream infections due to selected antimicrobial-resistant organismsiSH_BLD_MRSA: Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose

Goal 3Ensure healthy lives and promote well-being for all at all agesTarget 3.1: By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live birthsIndicator 3.1.1: Maternal mortality ratioSH_STA_MORT: Maternal mortality ratioIndicator 3.1.2: Proportion of births attended by skilled health personnelSH_STA_BRTC: Proportion of births attended by skilled health personnel (%)Target 3.2: By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live birthsIndicator 3.2.1: Under-5 mortality rateSH_DYN_IMRTN: Infant deaths (number)SH_DYN_MORT: Under-five mortality rate, by sex (deaths per 1,000 live births)SH_DYN_IMRT: Infant mortality rate (deaths per 1,000 live births)SH_DYN_MORTN: Under-five deaths (number)Indicator 3.2.2: Neonatal mortality rateSH_DYN_NMRTN: Neonatal deaths (number)SH_DYN_NMRT: Neonatal mortality rate (deaths per 1,000 live births)Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseasesIndicator 3.3.1: Number of new HIV infections per 1,000 uninfected population, by sex, age and key populationsSH_HIV_INCD: Number of new HIV infections per 1,000 uninfected population, by sex and age (per 1,000 uninfected population)Indicator 3.3.2: Tuberculosis incidence per 100,000 populationSH_TBS_INCD: Tuberculosis incidence (per 100,000 population)Indicator 3.3.3: Malaria incidence per 1,000 populationSH_STA_MALR: Malaria incidence per 1,000 population at risk (per 1,000 population)Indicator 3.3.4: Hepatitis B incidence per 100,000 populationSH_HAP_HBSAG: Prevalence of hepatitis B surface antigen (HBsAg) (%)Indicator 3.3.5: Number of people requiring interventions against neglected tropical diseasesSH_TRP_INTVN: Number of people requiring interventions against neglected tropical diseases (number)Target 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-beingIndicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory diseaseSH_DTH_NCOM: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease (probability)SH_DTH_NCD: Number of deaths attributed to non-communicable diseases, by type of disease and sex (number)Indicator 3.4.2: Suicide mortality rateSH_STA_SCIDE: Suicide mortality rate, by sex (deaths per 100,000 population)SH_STA_SCIDEN: Number of deaths attributed to suicide, by sex (number)Target 3.5: Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcoholIndicator 3.5.1: Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disordersSH_SUD_ALCOL: Alcohol use disorders, 12-month prevalence (%)SH_SUD_TREAT: Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders (%)Indicator 3.5.2: Alcohol per capita consumption (aged 15 years and older) within a calendar year in litres of pure alcoholSH_ALC_CONSPT: Alcohol consumption per capita (aged 15 years and older) within a calendar year (litres of pure alcohol)Target 3.6: By 2020, halve the number of global deaths and injuries from road traffic accidentsIndicator 3.6.1: Death rate due to road traffic injuriesSH_STA_TRAF: Death rate due to road traffic injuries, by sex (per 100,000 population)Target 3.7: By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmesIndicator 3.7.1: Proportion of women of reproductive age (aged 15–49 years) who have their need for family planning satisfied with modern methodsSH_FPL_MTMM: Proportion of women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (% of women aged 15-49 years)Indicator 3.7.2: Adolescent birth rate (aged 10–14 years; aged 15–19 years) per 1,000 women in that age groupSP_DYN_ADKL: Adolescent birth rate (per 1,000 women aged 15-19 years)Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for allIndicator 3.8.1: Coverage of essential health servicesSH_ACS_UNHC: Universal health coverage (UHC) service coverage indexIndicator 3.8.2: Proportion of population with large household expenditures on health as a share of total household expenditure or incomeSH_XPD_EARN25: Proportion of population with large household expenditures on health (greater than 25%) as a share of total household expenditure or income (%)SH_XPD_EARN10: Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%)Target 3.9: By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contaminationIndicator 3.9.1: Mortality rate attributed to household and ambient air pollutionSH_HAP_ASMORT: Age-standardized mortality rate attributed to household air pollution (deaths per 100,000 population)SH_STA_AIRP: Crude death rate attributed to household and ambient air pollution (deaths per 100,000 population)SH_STA_ASAIRP: Age-standardized mortality rate attributed to household and ambient air pollution (deaths per 100,000 population)SH_AAP_MORT: Crude death rate attributed to ambient air pollution (deaths per 100,000 population)SH_AAP_ASMORT: Age-standardized mortality rate attributed to ambient air pollution (deaths per 100,000 population)SH_HAP_MORT: Crude death rate attributed to household air pollution (deaths per 100,000 population)Indicator 3.9.2: Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (exposure to unsafe Water, Sanitation and Hygiene for All (WASH) services)SH_STA_WASH: Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)Indicator 3.9.3: Mortality rate attributed to unintentional poisoningSH_STA_POISN: Mortality rate attributed to unintentional poisonings, by sex (deaths per 100,000 population)Target 3.a: Strengthen the implementation of the World Health Organization Framework Convention on Tobacco Control in all countries, as appropriateIndicator 3.a.1: Age-standardized prevalence of current tobacco use among persons aged 15 years and olderSH_PRV_SMOK: Age-standardized prevalence of current tobacco use among persons aged 15 years and older, by sex (%)Target 3.b: Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for allIndicator 3.b.1: Proportion of the target population covered by all vaccines included in their national programmeSH_ACS_DTP3: Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)SH_ACS_MCV2: Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)SH_ACS_PCV3: Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)SH_ACS_HPV: Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) (%)Indicator 3.b.2: Total net official development assistance to medical research and basic health sectorsDC_TOF_HLTHNT: Total official development assistance to medical research and basic heath sectors, net disbursement, by recipient countries (millions of constant 2018 United States dollars)DC_TOF_HLTHL: Total official development assistance to medical research and basic heath sectors, gross disbursement, by recipient countries (millions of constant 2018 United States dollars)Indicator 3.b.3: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basisSH_HLF_EMED: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis (%)Target 3.c: Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing StatesIndicator 3.c.1: Health worker density and distributionSH_MED_DEN: Health worker density, by type of occupation (per 10,000 population)SH_MED_HWRKDIS: Health worker distribution, by sex and type of occupation (%)Target 3.d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risksIndicator 3.d.1: International Health Regulations (IHR) capacity and health emergency preparednessSH_IHR_CAPS: International Health Regulations (IHR) capacity, by type of IHR capacity (%)Indicator 3.d.2: Percentage of bloodstream infections due to selected antimicrobial-resistant organismsiSH_BLD_MRSA: Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose

ZA: Alcohol Consumption Rate: Projected Estimates: Aged 15+: Male data was reported at 16.200 NA in 2016. This records a decrease from the previous number of 18.400 NA for 2010. ZA: Alcohol Consumption Rate: Projected Estimates: Aged 15+: Male data is updated yearly, averaging 17.300 NA from Dec 2010 (Median) to 2016, with 2 observations. The data reached an all-time high of 18.400 NA in 2010 and a record low of 16.200 NA in 2016. ZA: Alcohol Consumption Rate: Projected Estimates: Aged 15+: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s South Africa – Table ZA.World Bank.WDI: Health Statistics. Total alcohol per capita consumption is defined as the total (sum of recorded and unrecorded alcohol) amount of alcohol consumed per person (15 years of age or older) over a calendar year, in litres of pure alcohol, adjusted for tourist consumption.; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Alcohol Addiction Treatments Market Outlook

The global Alcohol Addiction Treatments market size was valued at approximately USD 5.2 billion in 2023 and is expected to reach USD 8.1 billion by 2032, growing at a CAGR of 5.1% during the forecast period. This growth is primarily driven by increasing awareness about the adverse effects of alcohol abuse, coupled with the rise in government initiatives aimed at curbing alcohol addiction. Key growth factors include advancements in treatment options and the growing prevalence of alcohol dependence disorders worldwide.

One of the primary growth drivers for the Alcohol Addiction Treatments market is the increasing societal recognition of alcohol addiction as a significant public health issue. Governments and non-governmental organizations are launching campaigns to educate the public about the risks of alcohol abuse, thereby driving demand for treatment options. Policies aimed at reducing alcohol consumption and implementing stricter regulations on alcohol sales are also contributing to the market's growth. In addition, the increasing number of rehabilitation centers and specialty clinics focusing on treating alcohol addiction is expanding the market.

Technological advancements in medical treatments and behavioral therapies are also playing a crucial role in market growth. New medications designed to reduce cravings and withdrawal symptoms, along with innovative behavioral therapies such as cognitive-behavioral therapy (CBT) and motivational interviewing, are proving highly effective in treating alcohol addiction. These advancements are not only enhancing the effectiveness of treatments but are also making them more accessible to a broader range of patients. Moreover, the integration of telemedicine and online support groups is providing additional avenues for individuals seeking help, thereby expanding the reach of treatment options.

The growing prevalence of alcohol dependence disorders is another significant factor driving the market. According to the World Health Organization (WHO), alcohol-related disorders are among the leading causes of disability and death globally. The increasing recognition of these disorders as a chronic disease that requires long-term treatment is fostering the growth of the alcohol addiction treatment market. Furthermore, the COVID-19 pandemic has exacerbated issues related to alcohol abuse, as stress and isolation have led to increased alcohol consumption, thereby heightening the need for effective treatment solutions.

From a regional perspective, North America holds a dominant position in the Alcohol Addiction Treatments market, owing to the high prevalence of alcohol use disorders and the presence of well-established healthcare infrastructure. Europe and Asia Pacific are also significant markets, driven by rising awareness and increasing investments in healthcare facilities. In contrast, regions such as Latin America and the Middle East & Africa are expected to witness slower growth due to limited healthcare infrastructure and lower awareness levels. However, initiatives aimed at improving healthcare accessibility and raising awareness about the dangers of alcohol abuse are expected to boost market growth in these regions over the forecast period.

Treatment Type Analysis

The segment of Medications in the Alcohol Addiction Treatments market includes drugs such as disulfiram, naltrexone, and acamprosate, which are designed to reduce cravings and manage withdrawal symptoms. These medications have been proven effective in clinical studies and are widely used in combination with other treatment modalities like behavioral therapies. The growth of this segment is driven by ongoing research and development activities aimed at discovering new pharmacological treatments that offer better efficacy and fewer side effects. The rising acceptance of medication-assisted treatment (MAT) among healthcare providers and patients alike is further bolstering this segment.

Behavioral Therapies represent another critical segment within the market. This includes a range of interventions such as cognitive-behavioral therapy (CBT), motivational interviewing, and contingency management. These therapies are essential for helping individuals change their drinking behaviors and develop coping strategies to maintain sobriety. The increasing adoption of evidence-based behavioral therapies is driving the growth of this segment. Moreover, advancements in telehealth services are making it easier for patients to access these therapies, thereby expanding their reach and effectiveness.

Datasets from Global Burden of Diseases Study 2019. Mortality, morbidity, prevalence, from use of tobacco, alcohol, opiates, cannabis, and other drugs, the aggregated indicator (Substance use disorders) in 1990-2017. ICD10 codes: I42.6, K70.03, Z72.0, F10-19. Territories: Global, Eastern Europe, Central Europe, Western Europe, Belarus, Russia. Methods. We used indicators of mortality, morbidity, prevalence, and years of life lost, taking into account the DALY disability from tobacco, alcohol, opiates, cannabis, and other drugs. Indicators of harmful health effects from psycho-active presented from 1990 to 2017. Variables standardized by age and sex. Keywords: global burden of diseases, alcohol, substance use, psychoactive substances.

Alcohol Dependency Treatment Market Outlook

The global alcohol dependency treatment market size was valued at approximately $12.5 billion in 2023 and is projected to reach $20.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period. The market growth is primarily driven by increasing awareness about the health impacts of alcohol dependency and advancements in treatment options.

One of the critical growth factors in the alcohol dependency treatment market is the increasing prevalence of alcohol use disorders globally. According to the World Health Organization (WHO), over 3 million deaths were attributed to alcohol consumption in 2019. This alarming statistic has compelled governments and health organizations to initiate campaigns and fund research to better understand and treat alcohol dependency, driving market growth. Additionally, the rising societal and economic costs associated with alcohol dependency have heightened the urgency for effective treatment solutions, further propelling market expansion.

Advancements in medical and therapeutic treatments have also significantly contributed to market growth. The introduction of novel medications and behavioral therapies has improved the success rates of alcohol dependency treatments. Technological advancements in detoxification programs and the development of personalized treatment plans are other factors enhancing the effectiveness of treatments. This progress in medical science encourages more individuals to seek help, thereby expanding the market base. Moreover, continuous R&D investments by pharmaceutical companies to develop more effective and less invasive treatment methods are boosting market dynamics.

The growing acceptance and integration of digital health solutions present another substantial growth factor. Telemedicine and online counseling services have made treatment more accessible, especially in remote and underserved areas. These digital solutions offer anonymity and convenience, which can be crucial factors for individuals reluctant to seek traditional treatment options. The rise of mobile health apps designed for monitoring alcohol consumption and providing real-time support is also driving market growth by making treatment more manageable and less intrusive.

Alcohol Abuse Monitoring has become an integral part of the treatment landscape, offering critical insights into consumption patterns and helping tailor interventions more effectively. With the advent of wearable technology and mobile applications, real-time monitoring of alcohol intake is now possible, providing both patients and healthcare providers with valuable data. This technology not only aids in identifying triggers and high-risk situations but also enhances patient accountability. By integrating Alcohol Abuse Monitoring into treatment plans, healthcare professionals can offer more personalized and timely support, ultimately improving treatment outcomes. The continuous feedback loop created by these monitoring tools empowers individuals to take control of their recovery journey, fostering a proactive approach to managing alcohol dependency.

From a regional perspective, North America holds a significant share of the alcohol dependency treatment market due to the high prevalence of alcohol use disorders and well-established healthcare infrastructure. Europe follows closely, driven by substantial government and non-governmental initiatives aimed at reducing alcohol dependency. The Asia Pacific region is expected to exhibit the highest growth rate due to increasing awareness, improving healthcare infrastructure, and rising disposable incomes. Latin America, the Middle East, and Africa also show promising growth potential, albeit at a slower rate compared to other regions, due to various socio-economic factors and limited healthcare infrastructure.

Treatment Type Analysis

In the realm of treatment types, medications have emerged as a critical component in the comprehensive approach to alcohol dependency treatment. Medications such as disulfiram, naltrexone, and acamprosate are widely used to manage withdrawal symptoms and reduce cravings. The advent of new pharmacological innovations aims to improve patient compliance and minimize side effects, thereby enhancing the overall effectiveness of the treatment. As more pharmaceutical companies invest in R&D, the medications segment is expected to experience significant growth. Moreover, the increasing availability